Capsida 基因治疗临床试验致死后,研究者公布改善猴子风险检测的方法
STAT+: After death in gene therapy trial for a brain disease, progress is reported
Capsida Biotherapeutics 研究人员公布了一项针对基因治疗临床试验中患者死亡的调查结果,提出用改进方法检测猴子中的新型风险。研究未确认导致该患者死亡的确切原因。首席研究与创新官 Nicholas Flytzanis 称正着手建立一套可测试和预测风险的框架,用于筛查未来疗法。
Capsida scientists suggest they have found better way to test risk in monkeys
![]()
By Jason Mast
Nov. 17, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases.
The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies.
“What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief research and innovation officer at Capsida Biotherapeutics. “I think it can be tested, and I think this specific novel risk is one that we can try to mitigate and predict in the future.”
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
来源:STAT 主站 · statnews.com